Increases in aromatase and its proximal promoter I.3/II transcripts were also observed in these BRCA1 mutation carriers, supporting the hypothesis that with decreased BRCA1 function there is a dysregulation of aromatase transcription regulation and a predisposing factor to breast and ovarian cancer. The gene discussed is CYP19A1; the disease is ovarian cancer.